GTC Biotherapeutics (fka GTCB)

[icebrg]

I’m somewhat surprised by today’s CD20 announce-
ment because it takes guts to go head-to-head against
Genentech and BIIB, who are co-developing a second-
generation CD20 mAb called Ocrelizumab:

Further, there is a Genmab/GSK CD20 mAb in phase III.